Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) Financial Performance & Income Statement Overview
Review Alnylam Pharmaceuticals, Inc. (ALNY) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Alnylam Pharmaceuticals, Inc. ALNY financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $773.69M | $594.19M | $593.17M | $500.92M |
| Cost of Revenue | $0.00 | $71.04M | $102.82M | $85.91M |
| Gross Profit | $0.00 | $523.15M | $490.35M | $415.01M |
| Gross Profit Ratio | $0.00 | $0.88 | $0.83 | $0.83 |
| R&D Expenses | $323.62M | $265.12M | $300.17M | $270.93M |
| SG&A Expenses | $323.31M | $239.95M | $295.34M | $220.99M |
| Operating Expenses | $646.93M | $505.07M | $595.51M | $491.92M |
| Total Costs & Expenses | $789.89M | $576.11M | $698.33M | $577.82M |
| Interest Income | $27.49M | $28.67M | $31.02M | $32.15M |
| Interest Expense | -$40.25M | $38.65M | $38.97M | $34.38M |
| Depreciation & Amortization | $0.00 | $14.40M | $14.17M | $13.98M |
| EBITDA | -$16.20M | $11.46M | -$140.91M | -$60.30M |
| EBITDA Ratio | -$0.02 | $0.02 | -$0.24 | -$0.12 |
| Operating Income | -$16.20M | $18.08M | -$105.16M | -$76.91M |
| Operating Income Ratio | -$0.02 | $0.03 | -$0.18 | -$0.15 |
| Other Income/Expenses (Net) | -$19.16M | -$59.67M | -$88.80M | -$31.76M |
| Income Before Tax | -$35.36M | -$41.60M | -$193.96M | -$108.66M |
| Income Before Tax Ratio | -$0.05 | -$0.07 | -$0.33 | -$0.22 |
| Income Tax Expense | -$30.92M | $15.88M | -$110.19M | $2.91M |
| Net Income | -$66.28M | -$57.48M | -$83.76M | -$111.57M |
| Net Income Ratio | -$0.09 | -$0.10 | -$0.14 | -$0.22 |
| EPS | -$0.51 | -$0.44 | -$0.65 | -$0.87 |
| Diluted EPS | -$0.51 | -$0.44 | -$0.65 | -$0.87 |
| Weighted Avg Shares Outstanding | $130.63M | $129.68M | $128.59M | $128.59M |
| Weighted Avg Shares Outstanding (Diluted) | $130.63M | $129.68M | $128.59M | $128.59M |
Financial performance has remained strong, with revenue growing from $500.92M in Q3 2024 to $773.69M in Q2 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$16.20M in Q2 2025, holding a steady -2% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$16.20M. Net income dropped to -$66.28M, keeping EPS at -$0.51. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan